Hetrombopag Olamine is a synthetic, orally active thrombopoietin receptor (TPO-R) agonist used to stimulate platelet production. It is a small-molecule pharmaceutical compound developed for the treatment of thrombocytopenia associated with conditions such as immune thrombocytopenia and severe aplastic anemia.
Hetrombopag is administered in its olamine salt form and acts by activating the thrombopoietin receptor (c-Mpl), promoting the proliferation and differentiation of megakaryocytes and increasing platelet production.
The molecular formula of Hetrombopag Olamine is C29H38N6O4 and its molecular weight is approximately 534.66 g/mol. The CAS Number is 1370889-36-7.
Hetrombopag Olamine is a non-peptide thrombopoietin receptor agonist. Unlike endogenous thrombopoietin, which is a protein hormone, Hetrombopag is a small molecule that stimulates the TPO receptor and promotes platelet production.
It is used in pharmaceutical development for oral therapies intended to increase platelet counts in patients with selected thrombocytopenic disorders.
Hetrombopag binds to and activates the thrombopoietin receptor (TPO-R/c-Mpl) on megakaryocyte precursor cells.
TPO receptor activation stimulates intracellular signaling pathways involved in:
Hetrombopag Olamine API is used in the development and manufacture of pharmaceutical formulations for:
Hetrombopag Olamine is a synthetic pharmaceutical active ingredient manufactured through controlled chemical synthesis, purification and drying processes.
Quality control may include identification, assay, related substances, residual solvents, water content, elemental impurities and other parameters specified in the applicable API specification.
Hetrombopag Olamine is a synthetic small-molecule compound supplied as a solid pharmaceutical material. Its salt form is selected for pharmaceutical development and formulation purposes.
Hetrombopag Olamine should be stored in a tightly closed container, protected from excessive moisture, heat and direct light. Storage should comply with the manufacturer's current CoA, SDS and validated stability requirements.
Depending on the intended pharmaceutical application, documentation may include:
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |